Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) [Phase 3]
This Phase 3 trial compares pevonedistat plus azacitidine versus azacitidine alone as first-line therapy for higher-risk myelodysplastic syn…
-
CLINICAL_TRIALS trial_result · 2022-08-01Clinical Trial Update: Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 2]
Phase 2 clinical trial evaluating a combined regimen including iodine-131 monoclonal antibody BC8, fludarabine phosphate, total body irradia…
-
CLINICAL_TRIALS trial_result · 2022-07-19Clinical Trial Update: Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole [Phase 2]
A Phase 2 clinical trial evaluating peripheral blood stem cell transplantation from family haploidentical donors in patients with myelodyspl…
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: Prophylactic Application of Donor-derived TCM After Allogeneic HSCT [Phase 1, Phase 2]
A Phase 1/2 clinical trial investigated prophylactic use of donor-derived TCM after allogeneic hematopoietic stem cell transplantation, comp…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) [Phase 3]
Phase 3 trial results for APR-246 (eprenetapopt) in combination with azacitidine for TP53-mutant myelodysplastic syndromes have been complet…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2022-07-12Clinical Trial Update: Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant [Phase 1, Phase 2]
A Phase 1/2 safety study evaluating gene-modified donor T-cells after partially mismatched stem cell transplantation in patients with leukem…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant [Phase 1, Phase 2]
Clinical trial update for a phase 1/2 study evaluating gene-modified donor T-cells after TCR alpha beta–negative depleted stem cell transpla…
-
CLINICAL_TRIALS trial_result · 2022-07-07Clinical Trial Update: CPX-351 in Higher Risk Myelodysplastic Syndromes [Phase 1, Phase 2]
Phase 1/2 trial updates for CPX-351 in higher-risk myelodysplastic syndromes have been completed.
-
EMA withdrawal · 2022-07-05EMA Withdrawn: Imatinib Actavis (imatinib) — Actavis Group PTC ehf
EMA withdrawn Imatinib Actavis (imatinib) from the market, with indications including chronic myeloid leukemia, precursor B-ALL/lymphoma, my…
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study. [Phase 2]
A phase 2 prospective open-label single-arm trial evaluating hetrombopag for lower-risk myelodysplastic syndromes with thrombocytopenia.
-
FDA approval · 2022-05-20FDA Approved: VIDAZA — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for Vidaza (azacitidine) submitted by Celgene Corporation.
-
CLINICAL_TRIALS trial_result · 2022-04-20Clinical Trial Update: RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT [Phase 2]
Phase 2 clinical trial update on a RIC regimen for low- and intermediate-risk myelodysplastic syndromes undergoing haploidentical hematopoie…
-
FDA approval · 2022-04-15FDA Approved: DECITABINE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s generic decitabine via an Original Application, enabling the same indications as the brand pro…
-
CLINICAL_TRIALS trial_result · 2022-04-01Clinical Trial Update: CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. [Phase 1, Phase 2]
Clinical trial update for CIK-Cells in relapsing patients with acute leukemia or myelodysplastic syndromes after stem cell transplant (Phase…
-
CLINICAL_TRIALS trial_result · 2022-03-28Clinical Trial Update: Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT [Phase 1, Phase 2]
This clinical trial evaluates the safety and efficacy of γδ T cell therapy after allogeneic hematopoietic stem cell transplantation in hemat…
-
FDA approval · 2022-03-24FDA Approved: INQOVI — Supplemental Application (Taiho Pharmaceutical Co., Ltd.)
The FDA approved a supplemental application for INQOVI, the oral fixed-dose combination of cedazuridine and decitabine from Taiho Pharmaceut…
-
CLINICAL_TRIALS trial_result · 2022-03-15Clinical Trial Update: Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy [Phase 4]
Clinical trial comparing azacitidine plus HAG regimen versus azacitidine in elderly patients with newly diagnosed myeloid malignancies; phas…
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes [Phase 2]
Phase 2 clinical trial of selinexor (KPT-330), a selective inhibitor of nuclear export, in patients with myelodysplastic syndromes has compl…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes [Phase 2]
Phase 2 trial of pracinostat with azacitidine in high-risk myelodysplastic syndromes terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2022-01-28Clinical Trial Update: Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes [Phase 2]
Phase 2 trial update evaluating eltrombopag for thrombocytopenia in patients with low- to intermediate-risk myelodysplastic syndromes (MDS).
-
CLINICAL_TRIALS trial_result · 2022-01-03Clinical Trial Update: Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial evaluating azacitidine with or without ATRA in newly diagnosed unfit acute myeloid leukemia or intermediate…
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301) [Phase 3]
Phase 3 trial update for calcineurin inhibitor–free interventions to prevent graft-versus-host disease after transplantation has completed; …
-
CLINICAL_TRIALS trial_result · 2021-11-02Clinical Trial Update: A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) [Phase 2]
A Phase 2 dose-confirmation study of oral clofarabine in adults previously treated for myelodysplastic syndromes (MDS) has completed; result…
-
CLINICAL_TRIALS trial_result · 2021-10-04Clinical Trial Update: Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT [Phase 1, Phase 2]
Clinical trial update on ex-vivo primed memory donor lymphocyte infusion to boost antiviral immunity after T-cell depleted hematopoietic ste…
-
CLINICAL_TRIALS trial_result · 2021-09-24Clinical Trial Update: Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) [Phase 2]
Phase 2 clinical trial evaluating a conditioning regimen (busulfan, melphalan, fludarabine) with peri-transplant palifermin followed by T-ce…